Viking Therapeutics ( (VKTX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Viking Therapeutics shares are sliding as investors react to heavy selling by big institutional holders and company insiders, sparking worries about confidence in the stock. Large reductions by funds like Braidwell LP and Granahan Investment Management, along with sales by the CFO and directors, have intensified the downside move.
The drop is being fueled further by concerns over rising cash burn and sharply higher R&D costs as Viking pushes its obesity drug VK2735 into expensive Phase 3 trials. Analysts note that market sentiment has turned more cautious on the company’s ability to fund its late-stage pipeline, especially against a backdrop of broader market volatility.
More about Viking Therapeutics
YTD Price Performance: 0.99%
Average Trading Volume: 2,974,864
Technical Sentiment Signal: Buy
Current Market Cap: $4.11B
For further insights into VKTX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.